Outcomes of an HIV cohort after a decade of comprehensive care at Newlands Clinic in Harare, Zimbabwe: TENART cohort

Tinei Shamu, Cleophas Chimbetete, Sandra Shawarira-Bote, Tinashe Mudzviti, Ruedi Luthy, Tinei Shamu, Cleophas Chimbetete, Sandra Shawarira-Bote, Tinashe Mudzviti, Ruedi Luthy

Abstract

Background: Data on long-term outcomes of patients receiving antiretroviral therapy (ART) in sub-Saharan Africa are few. We describe outcomes of patients commenced on ART at Newlands Clinic between 2004 and 2006 after ≥10 years of comprehensive care including, psychosocial, adherence and food support.

Methods: In this retrospective cohort study, patient data from an electronic medical record collected during routine care were analysed. We describe baseline characteristics, virological and clinical outcomes, attrition rates, and treatment adverse effects until November 2016. We defined virological suppression as viral load <50 copies/ml and virological failure as >1000 copies/ml after ≥6 months of ART.

Results: We analysed data for 605 patients (67% female) who commenced ART, and were followed-up for 5819 person-years (median: 10.7 years, IQR: 10.1-11.4). Median age at ART initiation was 34 years (IQR: 17-42). Pre-ART, 129 (21.3%) patients had history of pulmonary tuberculosis (PTB). In care, 66 (11%) developed PTB, and 24 (4%) developed extrapulmonary tuberculosis. 385 (63.6%) patients experienced ≥1 adverse event, the most frequent being stavudine-induced peripheral neuropathy (n = 252, 41.7%). At database closure on 14 November 2016, 474 (78.3%) patients were still in care, 428 (90.3%) being virologically suppressed, and 21 (4.4%) failing. While 483 (79.8%) remained on first line, 122 (20.2%) were switched to second line ART. Fifty-nine patients (9.8%) were transferred to other ART facilities, 45 (7.4%) were lost to follow-up, 25 (4.1%) died, and two stopped ART.

Conclusion: Comprehensive HIV care can result in low mortality, high retention in care and virologic suppression rates in resource limited settings.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

References

    1. Zimbabwe Ministry of Health and Child Care, PEPFAR, ICAP, Agency N. Zimbabwe Population-Based HIV Impact Assessment (ZIMPHIA) 2015–2016. 2016.
    1. UNAIDS. Global AIDS Response Progress Reporting 2015. Geneva, Switzerland;
    1. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS. 2008;22: 1897–908. doi:
    1. Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007–2009: systematic review. Trop Med Int Health. 2010;15 Suppl 1: 1–15. doi:
    1. Boulle A, Orrel C, Kaplan R, Van Cutsem G, McNally M, Hilderbrand K, et al. Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antivir Ther. 2007;12: 753–60.
    1. Bussmann H, Wester CW, Ndwapi N, Grundmann N, Gaolathe T, Puvimanasinghe J, et al. Five-year outcomes of initial patients treated in Botswanaʼs National Antiretroviral Treatment Program. AIDS. 2008;22: 2303–2311. doi:
    1. Abaasa AM, Todd J, Ekoru K, Kalyango JN, Levin J, Odeke E, et al. Good adherence to HAART and improved survival in a community HIV/AIDS treatment and care programme: the experience of The AIDS Support Organization (TASO), Kampala, Uganda. BMC Health Serv Res. 2008;8: 241 doi:
    1. Chasombat S, McConnell MS, Siangphoe U, Yuktanont P, Jirawattanapisal T, Fox K, et al. National Expansion of Antiretroviral Treatment in Thailand, 2000–2007: Program Scale-Up and Patient Outcomes. JAIDS J Acquir Immune Defic Syndr. 2009;50: 506–512. doi:
    1. Mermin J, Were W, Ekwaru JP, Moore D, Downing R, Behumbiize P, et al. Mortality in HIV-infected Ugandan adults receiving antiretroviral treatment and survival of their HIV-uninfected children: a prospective cohort study. Lancet. 2008;371: 752–759. doi:
    1. Zhang F, Dou Z, Ma Y, Zhao Y, Liu Z, Bulterys M, et al. Five-year outcomes of the China National Free Antiretroviral Treatment Program. Ann Intern Med. 2009;151: 241–51, NaN-52.
    1. Weigel R, Estill J, Egger M, Harries AD, Makombe S, Tweya H, et al. Mortality and loss to follow-up in the first year of ART: Malawi national ART programme. AIDS. NIH Public Access; 2012;26: 365–73. doi:
    1. [Internet].
    1. Advisory, National Drug and Therapeutics Policy (NDTPAC), Committee And The AIDS and TB Unit, Ministry of Health and Child Welfare Z. Guidelines for Antiretroviral Therapy in Zimbabwe. 2010.
    1. National Medicine and Therapeutics Policy Advisory. Guidelines for Antiretroviral Therapy for the Prevention and Treatment of HIV in Guidelines for Prevention and Treatment of HIV in Zimbabwe, 2013. NMTPAC, MOHCC, editors. 2013.
    1. Art T. . In: . pp. 208–233.
    1. Mutasa-Apollo T, Shiraishi RW, Takarinda KC, Dzangare J. Patient Retention, Clinical Outcomes and Attrition-Associated Factors of HIV-Infected Patients Enrolled in Zimbabwe’s National Antiretroviral Therapy Programme, 2007–2010. Fox MP , editor. PLoS One. Public Library of Science; 2014;9: e86305 doi:
    1. May MT, Vehreschild J-J, Trickey A, Obel N, Reiss P, Bonnet F, et al. Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study; for the Antiretroviral Therapy Cohort Collaboration (ART-CC) a. doi:
    1. Pierre S, Jannat-Khah D, Fitzgerald DW, Pape J, McNairy ML. 10-Year Survival of Patients with AIDS Receiving Antiretroviral Therapy in Haiti. N Engl J Med. Massachusetts Medical Society; 2016;374: 397–398. doi:
    1. Fatti G, Mothibi E, Shaikh N, Grimwood A. Improved long-term antiretroviral treatment outcomes amongst patients receiving community-based adherence support in South Africa. AIDS Care. 2016;28: 1365–1372. doi:
    1. Johannessen A, Naman E, Kivuyo SL, Kasubi MJ. Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural Tanzania. BMC Infect Dis. BioMed Central; 2009;9: 108 doi:
    1. Castelnuovo B, Kiragga A, Kamya MR, Manabe Y. Stavudine toxicity in women is the main reason for treatment change in a 3-year prospective cohort of adult patients started on first-line antiretroviral treatment in Uganda. J Acquir Immune Defic Syndr. 2011;56: 59–63. doi:

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir